DOI: https://doi.org/10.24959/ubphj.19.234

Study physico-chemical and biopharmaceutical properties of poor soluble substances for predicting composition and technology of solid dosage forms

O. E. Schykovskiy, T. V. Krutskikh, A. A. Chehrynets

Abstract


Topicality. A detailed study of the physicochemical and biopharmaceutical properties of medicinal substances
should be carried out at the initial stage of the pharmaceutical development of the finished dosage form of a drug in order to avoid destructive transformations that can occur in the process of manufacture and storage, prediction of bioavailability, pharmacological efficacy and safety of medicinal products in the human body, as well as speed up the scientific work to determine the optimal composition and technology for new drugs.
Aim. To study a physico-chemical and biopharmaceutical properties of the poor soluble medicinal substances riluzole and nimodipine for predicting the optimal composition and technology of generic drugs.
Materials and methods. Samples of riluzole and nimodipine substances are obtained according to the technology, which is developed by the laboratory of chemical synthesis of the PJSC “Borshchahivskiy CPP”(Kiev, Ukraine) and also samples of tablets original drugs Rilutek, film-coated tablets, 50 mg, company “Sanofi”, France and Nimotop, film-coated tablets, 30 mg, company “Bayer AG”, Germany. All analytical and pharmaco-technological researches were implemented
according to generally accepted methods that accordance with the requirements of the State Pharmacopoeia of Ukraine.
Results and discussion. Physicochemical properties such as the chemical structure of molecules, the size and shape of particles of substances, the possibility of chemical interaction of substances with different excipients, the melting temperature, lipophilicity and solubility in organic and aqueous solvents for the substances riluzole and nimodipine were studied. The study of the biopharmaceutical properties of substances was carried out by study in vitro release kinetics of the substances riluzole and nimodipine from the tablets of the original drugs “Rilutec” and “Nimotop”.
Conclusions. Studies of the physico-chemical and biopharmaceutical properties of the medicinal substances riluzole and nimodipine made it possible to predict compatibility of substances with excipients and suggest the most optimal technology for generic drugs Borizol 50 mg film-coated tablets and Nimodipine 30 mg film-coated tablets.


Keywords


physico-chemical and biopharmaceutical properties; medicinal substance; riluzol; nimodipine; tablets; generic drug; Rilutek, Nimotop

References


Tykhonov, O. I., Yarnykh, T. H., Zupanets, I. A., Bezdietko, N. A., Dankevych, O. S., Bohutska, O. Ye., Azarenko, Yu. M., Levachkova, Yu. V. (2010). Biofarmatsiia: pidruchnyk dlia studentiv farmatsevtychnykh vuziv i fakultetiv. Kharkiv : NFaU; Zoloti storinky, 240.

Guidance “Medicines. (2011). Pharmaceutical Development (ICH Q8), Ministry of health 42.3.0: 2011”. Kiev, 33.

Yihong, Q., Yisheng, C., Geoff, Z., Lirong, L., Porter, W. (2009). Developing solid oral dosage forms pharmaceutical theory and practice. Academic

Press, 978. https://doi.org/10.1016/b978-0-444-53242-8.x0001-x

Guidance for Industry. (2000). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.

Gureyeva S. M., Albedhani O. S., Groshoviy T. A. (2015). Actual questions of pharmaceutical and medical science and practice, 3 (19), 38–43. https://doi.org/10.14739/2409-2932.2015.3.52383

Derzhavna Farmakopeia Ukrainy. (2001). DP “Naukovo-ekspertnyi farmakopeinyi tsentr”, (1–edition). Kharkiv : RIREH

DrugBank – database of medicinal products. (n.d.). Available at : the substance of riluzole – https://www.drugbank.ca/drugs/DB00740 and substance

nemodipine – https://www.drugbank.ca/drugs/DB00393

Rowe, R. C., Sheskey, P. J., Cook, W. G., Fenton, M. E. (2013). Handbook of Pharmaceutical Excipients. 7–th edition, 1064.

Grunenberg, A., Wirges, H. (1999). Polymorphism of nimodipine. 14th Industrial crystallization, 230.

Gladukh, E. V., Ruban, А. А., Saiko, I. V. (2016). Promyslova tekhnolohiia likarskykh zasobiv. Kharkiv : NFaU, 632.

Edward, H. Kerns, Li, Di. (2008). Drug-like Properties: Concepts, Structure Design and Methods: from ADME to toxicity optimization, 552.

Gowthamarajan, K., Sachin, K. (2010). Dissolution Testing for poorly soluble drugs: A Continuing Perspective. Dissolution Technologies, 17 (4), 24–32. https://doi.org/10.14227/dt170310p24


GOST Style Citations


1. Біофармація : підруч. для студ. фармац. вузів і факультетів / О. І. Тихонов, Т. Г. Ярних, І. А. Зупанець та ін. – Х. : Вид–во НФаУ ; Золоті сторінки, 2010. – 240с.


2. Настанова «Лікарські засоби. Фармацевтична розробка (ICH Q8). СТ-Н МОЗУ 42.3.0:2011». – К., 2011. – 33 с.


3. Developing solid oral dosage forms pharmaceutical theory and practice / Y. Qiu, Y. Chen, G. Zhang et al. // Academic Press. – 2009. – 1 ed. – 978p. https://doi.org/10.1016/b978-0-444-53242-8.x0001-x


4. Guidance for Industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. – FDA, 2000.


5. Гуреєва, С. М. Застосування біофармацевтичної системи класифікації у розробці нових лікарських препаратів / С. М. Гуреєва, О. С. Альбедхані, Т. А. Грошовий // Акт. питання фармац. і мед. науки та практики. – 2015. – № 3 (19). – С. 38–43. https://doi.org/10.14739/2409-2932.2015.3.52383


6. Державна фармакопея України / Державне підприємство «Науково–експертний фармакопейний центр», 1–е вид. – Х. : РІРЕГ, 2001., Доп. 1. – Х. : РІРЕГ. – 2004., Доп. 2. – Х. : РІРЕГ. – 2008., Доп. 3. – Х. : РІРЕГ. – 2010.


7. DrugBank – база даних лікарських препаратів [Електронний ресурс]. – Режим доступу : субстанція рилузол – https://www.drugbank.ca/drugs/DB00740 та субстанція німодипін – https://www.drugbank.ca/drugs/DB00393.


8. Handbook of Pharmaceutical Excipients / ed. by R. C. Rowe, P. J. Sheskey, W. G. Cook, M. E. Fenton – 7–th ed. – London : Pharmaceutical Press, 2013. – 1064 p.


9. Polymorphism of nimodipine / A. Grunenberg, H. Wirges. – 14th Industrial crystallization, 1999.


10. Промислова технологія лікарських засобів : Базовий підручник для студ. вищ. навч. фармац. закладу (фармац. факультетів) / Є. В. Гладух, О. А. Рубан, І. В. Сайко та ін. – Х. : НФаУ : Оригінал, 2016. – 632 с.


11. Edward, H. Kerns. Drug–like properties : concepts, structure design and methods: from ADME to toxicity optimization / E. Kerns and L. Di. – 1st ed. Academic press, 2008. – 552 p.


12. Gowthamarajan, K. Dissolution Testing for poorly soluble drugs : A Continuing Perspective / K. Gowthamarajan, K. Sachin // Dissolution Technol. –
2010. – Vol. 17 (3). – P. 24–32. https://doi.org/10.14227/dt170310p24





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Ukr. bìofarm. ž.

ISSN 2519-8750 (Online), ISSN 2311-715X (Print)